Le Lézard
Classified in: Health, Science and technology
Subjects: Filing, Statement

Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules")


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

No intention to bid statement for Horizon Therapeutics plc ("Horizon")

Further to the announcement by Horizon on November 29, 2022, Janssen Global Services, LLC ("the Company") confirmed today that it does not intend to make an offer for Horizon. Accordingly, the Company will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules. The Company reserves the right within the next 6 months to set aside this statement where so permitted under Rule 2.8 (including Rule 2.8(c)(ii)).

This announcement is intended to be treated as a statement to which Rule 2.8 of the Irish Takeover Rules applies.

Irish Takeover Rules

The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

This announcement is not intended to, and does not, constitute or form part of (i) an offer or invitation to purchase or otherwise acquire, subscribe for, tender, exchange, sell or otherwise dispose of any securities; (ii) the solicitation of an offer or invitation to purchase or otherwise acquire, subscribe for, tender, exchange, sell or otherwise dispose of any securities; or (iii) the solicitation of any vote or approval in any jurisdiction, pursuant to this announcement or otherwise.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.


These press releases may also interest you

at 15:00
Cognizant has extended its relationship with Orica, a leading manufacturer of commercial explosives and innovative blasting systems, to deliver an ESG data strategy and a digital platform, through agile methods, that provides real-time reporting and...

at 11:00
Minderoo Foundation's groundbreaking Plastic Waste Makers Index (PWMI) 2023 shows the planet's plastic pollution problem is worsening, and new estimates of lifecycle greenhouse gas emissions from single-use plastics demonstrate how single-use...

at 02:26
Appy Pie, a leading no-code app development platform with over 10 million registered users, has launched a new TV Commercial that keeps businesses of all sizes in focus. The commercial has been rolled out across US and UK TV networks and is also...

4 fév 2023
Capcon, a Singapore-based advanced packaging solution provider, has secured around $50 million in series B2 funding. The fund will mainly be invested in manufacturing, marketing, and R&D. Advanced packaging stands vital in sustaining Moore's Law....

4 fév 2023
DataSelf Corp., the mid-market leader in business analytics and data warehousing software, today announced that their reseller SWK Technologies, Inc. has achieved the top spot in sales revenue for 2022. Joni Girardi, DataSelf founder & CEO,...

4 fév 2023
Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)...



News published on 3 december 2022 at 17:15 and distributed by: